Kairos Pharma, Ltd. KAPA
At closeNov 4, 2026, 6:05 AM EST
Pre-market · Nov 4, 6:05 AM ET
- YTD
- -89.84%
- 1 year
- -91.68%
- Market cap
- 1.71M
- EPS (ttm)
- -1.96
- Shares out
- 12.85M
- Forward P/E
- -7.46
- YTD return
- -89.84%
- 1-year return
- -91.68%
- Volume
- 195.42K
- Avg volume
- 369.64K
- Open
- 0.47
- Previous close
- 0.4735
- Day's range
- 0.4182 – 0.505
- 52-week range
- 0.4182 – 7.28
- Price target
- 9.00 (+1682.2%)
6M -3.4350 (-87.18%)
Key statistics
- Enterprise value
- 17.13M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -41.75K
- Total cash
- 21.00K
- Total debt
- 783.00K
- Return on equity
- 0.00%
- Short % of float
- 0.00%
- 50-day average
- 1.54
- 200-day average
- 1.60
Analyst view
- Strong buy0
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.02.
Financials — quick view
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 14, 2024 | D. Boral Capital | main | Buy | Buy |
| Oct 14, 2024 | EF Hutton | init | — | Buy |
About Kairos Pharma, Ltd.
Kairos Pharma, Ltd., a clinical-stage biopharmaceutical company, develops therapeutics for cancer patients. Its therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. The company develops KROS 101 and 102, which are small molecules that are agonist and antagonist for the glucocorticoid induced TNF-like receptor ligand; KROS 201, an autologous T cell therapy targeting cancer stem cells of glioblastoma; KROS 301, a small molecule that targets the NF-?ß pathway, a cancer growth and immune suppressive molecule in triple negative breast cancer; and KROS 401, a cyclic peptide, which inhibits the IL-4 and IL-13 receptors. It also develops ENV 105, an antibody that targets CD105/Endoglin, which expressed in tumor cells and surrounding cells; and ENV 205, an antibody that targets mitochondrial DNA. Kairos Pharma, Ltd. was formerly known as NanoGB13, Inc. and changed its name to Kairos Pharma, Ltd. in July 2016. The company was incorporated in 2013 and is based in Los Angeles, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- kairospharma.com
News
Kairos Pharma Presents at United Scientific Group's 11th International Conference on Cancer Research & Drug Development 
12 Health Care Stocks Moving In Thursday's Pre-Market Session - 12 Health Care Stocks Moving In Wednesday's After-Market Session
12 Health Care Stocks Moving In Wednesday's Intraday Session 
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - 12 Health Care Stocks Moving In Tuesday's After-Market Session
Kairos Pharma Targets Drug Resistance Mechanism Against Prostate Cancer - 12 Health Care Stocks Moving In Tuesday's Intraday Session
Your note
Sign in to keep a note on KAPA — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Virtu Financial LLC | 0.25% | 32,711 | 56.10K | Sep 29, 2024 |
| HRT Financial LP | 0.10% | 12,609 | 21.62K | Sep 29, 2024 |